Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 6.62
RETA's Cash-to-Debt is ranked lower than
62% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. RETA: 6.62 )
Ranked among companies with meaningful Cash-to-Debt only.
RETA' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.62  Med: No Debt Max: No Debt
Current: 6.62
6.62
No Debt
Equity-to-Asset -1.09
RETA's Equity-to-Asset is ranked lower than
99% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RETA: -1.09 )
Ranked among companies with meaningful Equity-to-Asset only.
RETA' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.46  Med: -2.18 Max: -1.09
Current: -1.09
-3.46
-1.09
Debt-to-Equity -0.13
RETA's Debt-to-Equity is ranked lower than
99.99% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. RETA: -0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
RETA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13  Med: -0.13 Max: -0.13
Current: -0.13
Debt-to-EBITDA -0.43
RETA's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. RETA: -0.43 )
Ranked among companies with meaningful Debt-to-EBITDA only.
RETA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43  Med: -0.43 Max: -0.43
Current: -0.43
Piotroski F-Score: 1
Altman Z-Score: -2.32
Beneish M-Score: -1.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -97.62
RETA's Operating Margin % is ranked higher than
50% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. RETA: -97.62 )
Ranked among companies with meaningful Operating Margin % only.
RETA' s Operating Margin % Range Over the Past 10 Years
Min: -97.62  Med: -13.8 Max: 6.98
Current: -97.62
-97.62
6.98
Net Margin % -99.20
RETA's Net Margin % is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. RETA: -99.20 )
Ranked among companies with meaningful Net Margin % only.
RETA' s Net Margin % Range Over the Past 10 Years
Min: -99.2  Med: -12.49 Max: 1.33
Current: -99.2
-99.2
1.33
ROA % -43.79
RETA's ROA % is ranked lower than
57% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. RETA: -43.79 )
Ranked among companies with meaningful ROA % only.
RETA' s ROA % Range Over the Past 10 Years
Min: -43.79  Med: -7.41 Max: 0.39
Current: -43.79
-43.79
0.39
ROC (Joel Greenblatt) % -6270.83
RETA's ROC (Joel Greenblatt) % is ranked lower than
83% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. RETA: -6270.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RETA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6270.83  Med: -209.48 Max: 97.03
Current: -6270.83
-6270.83
97.03
GuruFocus has detected 4 Warning Signs with Reata Pharmaceuticals Inc RETA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RETA's 30-Y Financials

Financials (Next Earnings Date: 2018-08-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

RETA Guru Trades in

Q1 2017

RETA Guru Trades in Q1 2017

Jim Simons 24,670 sh (New)
» More
Q2 2017

RETA Guru Trades in Q2 2017

Jim Simons 35,200 sh (+42.68%)
» More
Q3 2017

RETA Guru Trades in Q3 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RETA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Reata Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:HKSE:01061, NAS:CMTA, XKRX:144510, XKRX:083790, NAS:ACRS, NAS:NCNA, NAS:PGNX, NAS:CDXS, OSTO:CAMX, ASX:MSB, NAS:ACHN, NAS:CASC, NAS:GLYC, XKRX:048530, TSX:TH, ROCO:4157, LSE:OXB, XKRX:141080, NAS:CNCE, NAS:AGEN » details
Traded in other countries:2R3.Germany,
Headquarter Location:USA
Reata Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in identifying, developing, and commercializing product candidates to address rare and life-threatening diseases by targeting molecular pathways.

Reata Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in identifying, developing, and commercializing product candidates to address rare and life-threatening diseases by targeting molecular pathways.

Top Ranked Articles about Reata Pharmaceuticals Inc

Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology
Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology
Report: Developing Opportunities within Repligen, Avid Technology, Reata Pharmaceuticals, Stellus Capital Investment, American Financial Group, and Actuant — Future Expectations, Projections Moving into 2018
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma

Ratios

vs
industry
vs
history
PS Ratio 11.73
RETA's PS Ratio is ranked higher than
53% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RETA: 11.73 )
Ranked among companies with meaningful PS Ratio only.
RETA' s PS Ratio Range Over the Past 10 Years
Min: 7.9  Med: 11.31 Max: 15.04
Current: 11.73
7.9
15.04
EV-to-EBIT -11.10
RETA's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. RETA: -11.10 )
Ranked among companies with meaningful EV-to-EBIT only.
RETA' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.6  Med: -30.5 Max: -8.9
Current: -11.1
-214.6
-8.9
EV-to-EBITDA -11.23
RETA's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. RETA: -11.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
RETA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -623.4  Med: -31.95 Max: -9
Current: -11.23
-623.4
-9
EV-to-Revenue 10.69
RETA's EV-to-Revenue is ranked higher than
58% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. RETA: 10.69 )
Ranked among companies with meaningful EV-to-Revenue only.
RETA' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.9  Med: 9.9 Max: 14
Current: 10.69
3.9
14
Current Ratio 2.80
RETA's Current Ratio is ranked lower than
63% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. RETA: 2.80 )
Ranked among companies with meaningful Current Ratio only.
RETA' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 1.67 Max: 2.8
Current: 2.8
1.27
2.8
Quick Ratio 2.80
RETA's Quick Ratio is ranked lower than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. RETA: 2.80 )
Ranked among companies with meaningful Quick Ratio only.
RETA' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 1.67 Max: 2.8
Current: 2.8
1.27
2.8

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.04
RETA's Price-to-Median-PS-Value is ranked higher than
54% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. RETA: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RETA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.8  Med: 1.02 Max: 1.23
Current: 1.04
0.8
1.23
Earnings Yield (Greenblatt) % -9.01
RETA's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. RETA: -9.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RETA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.2  Med: -3.25 Max: -0.5
Current: -9.01
-11.2
-0.5

More Statistics

Revenue (TTM) (Mil) $48.06
EPS (TTM) $ -1.99
Volatility50.30%
52-Week Range $19.31 - 40.88
Shares Outstanding (Mil)26.16

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}